{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:49:10Z","timestamp":1759160950776,"version":"3.37.3"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T00:00:00Z","timestamp":1475107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fondo de Investigaci\u00f3n de Sanidad (FIS)","award":["PI14CIII\/00011"],"award-info":[{"award-number":["PI14CIII\/00011"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD13\/00013"],"award-info":[{"award-number":["CD13\/00013"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD12\/00442"],"award-info":[{"award-number":["CD12\/00442"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondo de Investigac\u00f3n Sanitaria (FIS)","award":["CP13\/00098"],"award-info":[{"award-number":["CP13\/00098"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0163197","type":"journal-article","created":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T19:09:42Z","timestamp":1475176182000},"page":"e0163197","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain"],"prefix":"10.1371","volume":"11","author":[{"given":"Mar\u00eda \u00c1ngeles","family":"Jimenez-Sousa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Guti\u00e9rrez-Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"\u00c1lvaro-Meca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Garc\u00eda-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Richard","family":"Harrigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare Giovanni","family":"Fedele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Briz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0977-741X","authenticated-orcid":true,"given":"Sonia","family":"V\u00e1zquez-Mor\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Resino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,9,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/jvh.12422","article-title":"Interferon-free, direct-acting antiviral therapy for chronic hepatitis C","volume":"22","author":"JA Gutierrez","year":"2015","journal-title":"J Viral Hepat"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"C Sarrazin","year":"2016","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: State of the art summary","volume":"62","author":"E Lontok","year":"2015","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","article-title":"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies","volume":"62","author":"O Lenz","year":"2015","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1365-2893.2010.01342.x","article-title":"Evidence for separation of HCV subtype 1a into two distinct clades","volume":"18","author":"BE Pickett","year":"2011","journal-title":"J Viral Hepat"},{"key":"ref7","article-title":"Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients","author":"S Bagaglio","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"ofv043","DOI":"10.1093\/ofid\/ofv043","article-title":"Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors","volume":"2","author":"A De Luca","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1128\/AAC.00777-10","article-title":"Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors","volume":"54","author":"A Bae","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref10","article-title":"Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype 1-infected individuals","author":"LT Nguyen","year":"2015","journal-title":"Antivir Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cmi.2015.07.017","article-title":"Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK","volume":"21","author":"A Beloukas","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcv.2015.02.005","article-title":"Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort","volume":"65","author":"SJ Shepherd","year":"2015","journal-title":"J Clin Virol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jcv.2014.06.023","article-title":"Patients eligible for treatment with simeprevir in a French center","volume":"61","author":"V Morel","year":"2014","journal-title":"J Clin Virol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/jac\/dkr581","article-title":"Naturally occurring hepatitis C virus (HCV) NS3\/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy","volume":"67","author":"I Vicenti","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1097\/QAD.0b013e328363b1f9","article-title":"Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C","volume":"27","author":"M Leggewie","year":"2013","journal-title":"AIDS"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region","volume":"116","author":"C Sarrazin","year":"2015","journal-title":"Antiviral Res"},{"key":"ref17","article-title":"NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naive subjects","author":"LL Vidal","year":"2016","journal-title":"J Viral Hepat"},{"key":"ref18","article-title":"Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naive patients with chronic hepatitis: single-centre experience","author":"T Ruggiero","year":"2015","journal-title":"Arch Virol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1128\/AAC.03466-14","article-title":"Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV\/HIV coinfection","volume":"58","author":"CB Jabara","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"19741","DOI":"10.7448\/IAS.17.4.19741","article-title":"Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV\/HCV co-infected patients in a Berlin laboratory","volume":"17","author":"R Ehret","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"ref21","article-title":"Naturally occurring HCV protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV coinfection","author":"Y Cao","year":"2015","journal-title":"Hepatol Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3851\/IMP2873","article-title":"Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection","volume":"20","author":"G Lisboa-Neto","year":"2015","journal-title":"Antivir Ther"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/QCO.0b013e32835c2120","article-title":"Sexually transmitted hepatitis C infection: the new epidemic in MSM?","volume":"26","author":"D Bradshaw","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2174\/157016212803306023","article-title":"Substance abuse, HIV-1 and hepatitis","volume":"10","author":"N Parikh","year":"2012","journal-title":"Curr HIV Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/infdis\/jiu613","article-title":"Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism","volume":"211","author":"RM McCloskey","year":"2015","journal-title":"J Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0163197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T09:32:19Z","timestamp":1601112739000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0163197"}},"subtitle":[],"editor":[{"given":"Ranjit","family":"Ray","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,9,29]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0163197","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2016,9,29]]}}}